Skip to main content
Clinical Trials/NCT04202055
NCT04202055
Completed
Not Applicable

Immunologic Biomarker Profile of Cerebrospinal Fluid

Centre Hospitalier Universitaire de Nīmes1 site in 1 country165 target enrollmentJanuary 2, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Centre Hospitalier Universitaire de Nīmes
Enrollment
165
Locations
1
Primary Endpoint
Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The aim of this study was the describe the Immunologic biomarker profile of cerebrospinal fluid in multiple sclerosis patients

Registry
clinicaltrials.gov
Start Date
January 2, 2018
End Date
August 31, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Centre Hospitalier Universitaire de Nīmes
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients who have had neuromyelitis ptica with anti-AQP4 antibodies, or anti- Myelin Oligodendrocyte Glycoprotein antibodies, or double seronegative antibodies.
  • Neuromyelitis Optica patients have been prospectively included in the OFSEP collection
  • Multiple sclerosis patients, isolated myelitis or optic neuritis patients, and symptomatic controls whose samples will come from the "NEURO" collection of the Hospital Biological Collections Center,
  • Patients have given their free consent for use of their samples in research

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of glial fibrillar acidic protein in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of neurofilament in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Matrix metalloproteinase-9 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Soluble CD27 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Interleukin 10 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of chitinase-3-like protein 1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Interleukin-6 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Interleukin-8 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Interleukin 17A in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Level of Interleukin 1B in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein

Time Frame: Baseline

enzyme-linked immunosorbent assay

Secondary Outcomes

  • Level of neurofilament in cerebrospinal fluid in each group(Baseline)
  • Level of Interleukin-6 in cerebrospinal fluid in each group(Baseline)
  • Level of Interleukin 1B in cerebrospinal fluid in each group(Baseline)
  • Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in each group(Baseline)
  • Level of glial fibrillar acidic protein in cerebrospinal fluid in each group(Baseline)
  • Level of chitinase-3-like protein 1 in cerebrospinal fluid in each group(Baseline)
  • Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in each group(Baseline)
  • Level of Matrix metalloproteinase-9 in cerebrospinal fluid in each group(Baseline)
  • Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in each group(Baseline)
  • Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in each group(Baseline)
  • Level of Interleukin-8 in cerebrospinal fluid in each group(Baseline)
  • Level of Soluble CD27 in cerebrospinal fluid in each group(Baseline)
  • Level of Interleukin 10 in cerebrospinal fluid in each group(Baseline)
  • Level of Interleukin 17A in cerebrospinal fluid in each group(Baseline)

Study Sites (1)

Loading locations...

Similar Trials